Alector’s AL101 Receives FDA’s Fast Track Designation to Treat Frontotemporal Dementia

 Alector’s AL101 Receives FDA’s Fast Track Designation to Treat Frontotemporal Dementia

Alector’s AL101 Receives FDA’s Fast Track Designation to Treat Frontotemporal Dementia

Shots:

  • The US FDA has granted FT designation to Alector’s AL101 to treat patients with progranulin gene mutations causative of frontotemporal dementia (FTD-GRN), currently being evaluated in P-I study in healthy volunteers
  • The FDA’s FT designation is designed to facilitate the development and expedite the review of therapies for serious conditions targeting unmet medical needs of patients
  • AL101 is a mAb, designed to restore levels of progranulin in the CNS, currently in development for FTD-GRN, AD and PD and has received FDA’s ODD for FTD-GRN in July’2019

Click here ­to­ read full press release/ article | Ref: Alector | Image: Alector

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post